Ascendis Pharma Third Quarter 2024 Earnings: Misses Expectations

Ascendis Pharma (NASDAQ:ASND) Third Quarter 2024 Results

Key Financial Results

• Revenue: €57.8m (up 20% from 3Q 2023).
• Net loss: €99.2m (loss narrowed by 39% from 3Q 2023).
• €1.72 loss per share (improved from €2.88 loss in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ascendis Pharma Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 15%.

Looking ahead, revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 1.8% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Ascendis Pharma (at least 1 which is a bit concerning), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.